Stealth’s Elamipretide Gets US FDA Review, But Same Questions Linger

 
• By Derrick Gingery
conference room table
Elamipretide's NDA filing provides a seat at the table, but Stealth BioTherapeutics still has work to do, its CEO said. • Source: Shutterstock

More from Product Reviews

More from Pink Sheet